176 related articles for article (PubMed ID: 30191523)
21. The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Rehman OU; Nadeem ZA; Fatima E; Akram U; Imran H; Husnain A; Nadeem A; Rasheed W
Clin Genitourin Cancer; 2024 Apr; 22(2):483-490.e5. PubMed ID: 38296679
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
23. Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Tresnanda RI; Pramod SV; Safriadi F
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3101-3107. PubMed ID: 34710984
[TBL] [Abstract][Full Text] [Related]
24. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
25. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.
Kruczek K; Ratterman M; Tolzien K; Sulo S; Lestingi TM; Nabhan C
Br J Cancer; 2013 Oct; 109(7):1711-6. PubMed ID: 24008662
[TBL] [Abstract][Full Text] [Related]
26. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
27. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
28. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
[TBL] [Abstract][Full Text] [Related]
30. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Taplin ME; Regan MM; Ko YJ; Bubley GJ; Duggan SE; Werner L; Beer TM; Ryan CW; Mathew P; Tu SM; Denmeade SR; Oh WK; Sartor O; Mantzoros CS; Rittmaster R; Kantoff PW; Balk SP
Clin Cancer Res; 2009 Nov; 15(22):7099-105. PubMed ID: 19887483
[TBL] [Abstract][Full Text] [Related]
32. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
Chow H; Ghosh PM; deVere White R; Evans CP; Dall'Era MA; Yap SA; Li Y; Beckett LA; Lara PN; Pan CX
Cancer; 2016 Jun; 122(12):1897-904. PubMed ID: 27019001
[TBL] [Abstract][Full Text] [Related]
34. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.
Eigl BJ; North S; Winquist E; Finch D; Wood L; Sridhar SS; Powers J; Good J; Sharma M; Squire JA; Bazov J; Jamaspishvili T; Cox ME; Bradbury PA; Eisenhauer EA; Chi KN
Invest New Drugs; 2015 Aug; 33(4):969-76. PubMed ID: 25983041
[TBL] [Abstract][Full Text] [Related]
36. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.
Fujita K; Nakai Y; Kawashima A; Ujike T; Nagahara A; Nakajima T; Inoue T; Lee CM; Uemura M; Miyagawa Y; Kaneda Y; Nonomura N
Cancer Gene Ther; 2017 Jul; 24(7):277-281. PubMed ID: 28497777
[TBL] [Abstract][Full Text] [Related]
38. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Figg WD; Woo S; Zhu W; Chen X; Ajiboye AS; Steinberg SM; Price DK; Wright JJ; Parnes HL; Arlen PM; Gulley JL; Dahut WL
J Urol; 2010 Jun; 183(6):2219-26. PubMed ID: 20399458
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
Fujiwara M; Akamatsu S; Sumiyoshi T; Segawa T; Mizuno K; Yoshino T; Goto T; Sawada A; Saito R; Kobayashi T; Yamasaki T; Inoue T; Ogawa O
Clin Genitourin Cancer; 2019 Oct; 17(5):e923-e929. PubMed ID: 31307917
[TBL] [Abstract][Full Text] [Related]
40. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.
Ho TH; Nunez-Nateras R; Hou YX; Bryce AH; Northfelt DW; Dueck AC; Wong B; Stanton ML; Joseph RW; Castle EP
Clin Genitourin Cancer; 2017 Apr; 15(2):196-202.e1. PubMed ID: 27771244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]